Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Text message advice could keep kids with fever out of the ER

NCT ID NCT07248488

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving parents standardized fever advice during an emergency call plus a follow-up text message can reduce unnecessary doctor visits and ER trips for children aged 3 months to 10 years with uncomplicated fever. About 1,792 parents will be randomly assigned to receive either usual care or the enhanced advice and text message. The goal is to see if this simple, low-cost intervention improves how parents manage fever and reduces strain on the healthcare system.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
standardized recommendations and advisory text message
What this could lead to
If successful, this low-cost approach could reduce unnecessary emergency visits and help parents manage childhood fever at home more confidently.
What could go wrong
This is a relatively small, early-stage trial. The effect may be modest, and results might not apply to all regions or healthcare systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,792 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria relating to the child concerned by the call to the SAMU Centre 15: * Call for a child aged between 3 months and 10 years, * Presenting with fever alone (SFMU/GPIP definition), * Developing for less than 72 hours, * Without clinical signs, * And without signs of seriousness requiring emergency medical attention (as determined by SAMU Centre 15): * Fever ≥41°C, * Impaired consciousness, * Convulsions, * Dyspnea, * Skin rash, * Dehydration. Inclusion criteria relating to the caller: * Caller with parental authority over the child concerned by the call, * Affiliated to a social security scheme or beneficiary of a similar scheme. Exclusion criteria relating to children involved in calls to the SAMU Centre 15 emergency medical service: * Children who have already been the subject of a call to the SAMU Centre 15 emergency medical service in the last 15 days, * Children with a history of urinary tract infection, * Children referred by the dispatcher during the phone call to a healthcare facility for clinical evaluation (SMUR, private ambulance, fire department, parents referred to the emergency room or primary care physician). Exclusion criteria relating to the caller: * Calls made from a landline or foreign number, making it impossible to send text messages, * Calls made by someone who cannot read or understand French.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Emergency call are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Annecy Genevois

    Annecy, Auvergne-Rhône-Alpes, 74370, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.